Last reviewed · How we verify
Comparator: Influenza Vaccine
Influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains, providing protection against infection.
Influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains, providing protection against infection. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Comparator: Influenza Vaccine |
|---|---|
| Also known as | Fluzone, Vaxigrip |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | vaccine |
| Target | Influenza virus hemagglutinin and neuraminidase surface antigens |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated or attenuated influenza virus antigens that trigger both humoral (antibody-mediated) and cellular immune responses. This primes the immune system to recognize and rapidly respond to natural influenza infection, reducing disease severity and transmission risk. Annual reformulation targets circulating seasonal strains.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Fever
- Fatigue
Key clinical trials
- This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza (PHASE2)
- A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above (PHASE2)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- pH1N1 Blinded Challenge Study (PHASE1)
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE2)
- Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |